98
3 In-Tether Chiral Center Induced Helical Peptide Modulators …
6. Liu J et al (2009) Biorecognition and subcellular trafficking of HPMA copolymer—anti-PSMA
antibody conjugates by prostate cancer cells. Mol Pharm 6(3):959–970
7. Jin L et al (2006) Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat
Med 12(10):1167–1174
8. Liu F-S (2009) Mechanisms of chemotherapeutic drug resistance in cancer therapy—a quick
review. Taiwan J Obstet Gynecol 48(3):239–244
9. Moitra K et al (2011) Multidrug efflux pumps and cancer stem cells: insights into multidrug
resistance and therapeutic development. Clin Pharmacol Ther 89(4):491–502
10. Moellering RE et al (2009) Direct inhibition of the NOTCH transcription factor complex.
Nature 462(7270):182–188
11. Bird GH et al (2010) Hydrocarbon double-stapling remedies the proteolytic instability of a
lengthy peptide therapeutic. Proc Natl Acad Sci 107(32):14093–14098
12. Milroy L-G et al (2014) Modulators of protein-protein interactions. Chem Rev 114(9):4695–
4748
13. Hu K et al (2016) An in-tether chiral center modulates the helicity, cell permeability, and target
binding affinity of a peptide. Angew Chem Int Ed 55(28):8013–8017
14. Walensky LD et al (2004) Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 Helix.
Science 305(5689):1466–1470
15. Bernal F et al (2007) Reactivation of the p53 tumor suppressor pathway by a stapled p53
peptide. J Am Chem Soc 129(9):2456–2457
16. Grossmann TN et al (2012) Inhibition of oncogenic Wnt signaling through direct targeting of
β-catenin. Proc Natl Acad Sci 109(44):17942–17947
17. Vogelstein B et al (2000) Surfing the p53 network. Nature 408(6810):307–310
18. Haupt S et al (2003) Apoptosis—the p53 network. J Cell Sci 116(20):4077–4085
19. Cheok CF et al (2011) Translating p53 into the clinic. Nat Rev Clin Oncol 8(1):25–37
20. Hu B et al (2006) MDMX overexpression prevents p53 activation by the MDM2 inhibitor
nutlin. J Biol Chem 281(44):33030–33035
21. Mogi A, Kuwano H (2011) TP53 mutations in nonsmall cell lung Cancer. J Biomed Biotechnol
2011
22. Obrador-Hevia A et al (2015) RG7112, a small-molecule inhibitor of MDM2, enhances
trabectedin response in soft tissue sarcomas. Cancer Invest 33(9):440–450
23. Tovar C et al (2013) MDM2 small-molecule antagonist RG7112 activates p53 signaling and
regresses human tumors in preclinical cancer models. Can Res 73(8):2587–2597
24. Graves B et al (2012) Activation of the p53 pathway by small-molecule-induced MDM2 and
MDMX dimerization. Proc Natl Acad Sci 109(29):11788–11793
25. Brown CJ et al (2013) Stapled peptides with improved potency and specificity that activate
p53. ACS Chem Biol 8(3):506–512
26. Chang YS et al (2013) Stapled α − helical peptide drug development: a potent dual inhibitor
of MDM2 and MDMX for p53-dependent cancer therapy. Proc Natl Acad Sci U S A
110(36):E3445–E3454
27. Chung W-M et al (2013) MicroRNA-21 promotes the ovarian teratocarcinoma PA1 cell line
by sustaining cancer stem/progenitor populations in vitro. Stem Cell Res & Ther 4(4):1–10
28. Chung W-M et al (2014) Ligand-independent androgen receptors promote ovarian teratocarcinoma cell growth by stimulating self-renewal of cancer stem/progenitor cells. Stem Cell Res
13(1):24–35
29. Sekar D et al. Deciphering the role of microRNA 21 in cancer stem cells (CSCs). Genes &
Diseases
30. Yaginuma Y, Westphal H (1992) Abnormal structure and expression of the p53 gene in human
Ovarian carcinoma cell Lines. Can Res 52(15):4196–4199
31. Reich NC et al (1983) Two distinct mechanisms regulate the levels of a cellular tumor antigen,
p53. Mol Cell Biol 3(12):2143–2150
32. Wang L et al (2001) Analyses of p53 target genes in the human genome by bioinformatic and
microarray approaches. J Biol Chem 276(47):43604–43610
3 In-Tether Chiral Center Induced Helical Peptide Modulators …
6. Liu J et al (2009) Biorecognition and subcellular trafficking of HPMA copolymer—anti-PSMA
antibody conjugates by prostate cancer cells. Mol Pharm 6(3):959–970
7. Jin L et al (2006) Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat
Med 12(10):1167–1174
8. Liu F-S (2009) Mechanisms of chemotherapeutic drug resistance in cancer therapy—a quick
review. Taiwan J Obstet Gynecol 48(3):239–244
9. Moitra K et al (2011) Multidrug efflux pumps and cancer stem cells: insights into multidrug
resistance and therapeutic development. Clin Pharmacol Ther 89(4):491–502
10. Moellering RE et al (2009) Direct inhibition of the NOTCH transcription factor complex.
Nature 462(7270):182–188
11. Bird GH et al (2010) Hydrocarbon double-stapling remedies the proteolytic instability of a
lengthy peptide therapeutic. Proc Natl Acad Sci 107(32):14093–14098
12. Milroy L-G et al (2014) Modulators of protein-protein interactions. Chem Rev 114(9):4695–
4748
13. Hu K et al (2016) An in-tether chiral center modulates the helicity, cell permeability, and target
binding affinity of a peptide. Angew Chem Int Ed 55(28):8013–8017
14. Walensky LD et al (2004) Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 Helix.
Science 305(5689):1466–1470
15. Bernal F et al (2007) Reactivation of the p53 tumor suppressor pathway by a stapled p53
peptide. J Am Chem Soc 129(9):2456–2457
16. Grossmann TN et al (2012) Inhibition of oncogenic Wnt signaling through direct targeting of
β-catenin. Proc Natl Acad Sci 109(44):17942–17947
17. Vogelstein B et al (2000) Surfing the p53 network. Nature 408(6810):307–310
18. Haupt S et al (2003) Apoptosis—the p53 network. J Cell Sci 116(20):4077–4085
19. Cheok CF et al (2011) Translating p53 into the clinic. Nat Rev Clin Oncol 8(1):25–37
20. Hu B et al (2006) MDMX overexpression prevents p53 activation by the MDM2 inhibitor
nutlin. J Biol Chem 281(44):33030–33035
21. Mogi A, Kuwano H (2011) TP53 mutations in nonsmall cell lung Cancer. J Biomed Biotechnol
2011
22. Obrador-Hevia A et al (2015) RG7112, a small-molecule inhibitor of MDM2, enhances
trabectedin response in soft tissue sarcomas. Cancer Invest 33(9):440–450
23. Tovar C et al (2013) MDM2 small-molecule antagonist RG7112 activates p53 signaling and
regresses human tumors in preclinical cancer models. Can Res 73(8):2587–2597
24. Graves B et al (2012) Activation of the p53 pathway by small-molecule-induced MDM2 and
MDMX dimerization. Proc Natl Acad Sci 109(29):11788–11793
25. Brown CJ et al (2013) Stapled peptides with improved potency and specificity that activate
p53. ACS Chem Biol 8(3):506–512
26. Chang YS et al (2013) Stapled α − helical peptide drug development: a potent dual inhibitor
of MDM2 and MDMX for p53-dependent cancer therapy. Proc Natl Acad Sci U S A
110(36):E3445–E3454
27. Chung W-M et al (2013) MicroRNA-21 promotes the ovarian teratocarcinoma PA1 cell line
by sustaining cancer stem/progenitor populations in vitro. Stem Cell Res & Ther 4(4):1–10
28. Chung W-M et al (2014) Ligand-independent androgen receptors promote ovarian teratocarcinoma cell growth by stimulating self-renewal of cancer stem/progenitor cells. Stem Cell Res
13(1):24–35
29. Sekar D et al. Deciphering the role of microRNA 21 in cancer stem cells (CSCs). Genes &
Diseases
30. Yaginuma Y, Westphal H (1992) Abnormal structure and expression of the p53 gene in human
Ovarian carcinoma cell Lines. Can Res 52(15):4196–4199
31. Reich NC et al (1983) Two distinct mechanisms regulate the levels of a cellular tumor antigen,
p53. Mol Cell Biol 3(12):2143–2150
32. Wang L et al (2001) Analyses of p53 target genes in the human genome by bioinformatic and
microarray approaches. J Biol Chem 276(47):43604–43610